Sanofi said SAR446597, its treatment for geographic atrophy due to age-related macular degeneration, was granted fast-track designation by the Food and Drug Administration. The French drugmaker said ...

Autosomal dominant optic atrophy (ADOA), the most common genetic optic neuropathy, is an insidious disease. It often presents slowly during childhood by way of blurry vision, trouble reading or ...

Sanofi SNY has announced that the FDA has granted a fast-track designation to its one-time intravitreal gene therapy, SAR446597, for the treatment of geographic atrophy (GA) due to age-related macular ...

The new branding emphasizes the company's commitment to redefining the retina experience, particularly in the treatment of wet age-related macular degeneration (AMD), which affects millions of people.

A new study identifies how the molecule, called ApoM, can clear harmful cholesterol deposits linked to macular degeneration as well as certain types of heart ailments.

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic ...